Specifics of drug-drug interactions between rivaroxaban and a P-glycoprotein inhibitor depending on the CYP3A4/A5 gene polymorphism in patients aged 80 years and older with non-valvular atrial fibrillation

Abstract

BACKGROUND: An increased risk of bleeding during rivaroxaban administration is associated with polymorphism of genes involved in its biotransformation, as well as with the use of drugs inhibiting shared metabolic pathways. However, the data are inconsistent.

AIM: To study specifics of drug-drug interactions between rivaroxaban and a P-glycoprotein inhibitor (using verapamil as an example) depending on the polymorphism of the CYP3A4 (rs35599367) and CYP3A5 (rs776746) genes in patients aged 80 years and older with non-valvular atrial fibrillation.

MATERIALS AND METHODS: A total of 128 patients (median age 87.5 years [83; 90], 75% women) were examined. All patients underwent genotyping for the studied gene variants, determination of the minimum steady-state concentration of rivaroxaban (C_{min, ss}), standardization of the minimum steady-state concentration of rivaroxaban per daily dose (C_{min, ss}/D), determination of prothrombin time in plasma, and analysis of medical documentation for the occurrence of clinically significant minor bleeding.

RESULTS: Compared to patients receiving rivaroxaban without calcium channel blockers, co-administration of rivaroxaban and verapamil in carriers of the CC variant of the CYP3A4 gene resulted in higher values of C_{min, ss} (73.8 [49; 113.5] vs. 40.5 [25.6; 73.3] ng/mL), C_{min, ss}/D (2.5 [1.7; 4.0] vs. 4.7 [2.9; 7.7] ng/mL/mg), prothrombin time (14.8 [13.3; 17.3] vs. 14.0 [12.6; 14.5] s) and clinically significant minor bleeding [10/30 (33.3%) vs. 6/45 (13.3%) cases], p < 0.05. In carriers of the GG variant of the CYP3A5 gene, the same regimen resulted in higher values of C_{min, ss} (74.7 [50.6; 108.8] vs. 40.2 [25.7; 72.3] ng/mL), C_{min, ss}/D (4.6 [3.0; 7.3] vs. 2.5 [1.7; 4.0] ng/mL×mg), prothrombin time (14.6 [12.8; 15.2] vs. 14.0 [12.6; 14.5] s) and clinically significant minor bleeding [10/27 (37%) vs. 5/40 (12.5%) cases], p < 0.05. Furthermore, in carriers of the GA+AA variant of the CYP3A5 gene, this regimen resulted in higher values of C_{min, ss} (88.1 [5.5; 88.1] vs. 52.8 [25.0; 77.2] ng/mL), C_{min, ss}/D (5.7 [0.4; 5.7] vs. 3.5 [1.7; 5.2] ng/mL×mg), p < 0.05. The combined use of rivaroxaban with verapamil in carriers of the CT variant of the CYP3A4 gene was not observed in our sample.

CONCLUSIONS: Carriers of the homozygous wild-type CYP3A4/A5 genotype showed high pharmacokinetic variability to the administration of verapamil (a strong P-glycoprotein inhibitor and a moderate CYP3A4 inhibitor).

Keywords

drug-drug interactions / rivaroxaban / P-glycoprotein inhibitor / CYP3A4/5 / pharmacogenetics / elderly patient / bleeding

References

[1] Arakelyan MG, Bockeria LA, Vasilieva EYu, et al. 2020 Clinical guidelines for Atrial fibrillation and atrial flutter. Russian Journal of Cardiology. 2021;26(7):190–260. (In Russ.) EDN: FUZAAD doi: 10.15829/1560-4071-2021-4594

[2] Аракелян М.Г., Бокерия Л.А., Васильева Е.Ю., и др. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020 // Российский кардиологический журнал. 2021. Т. 26, № 7. C. 190–260. EDN: FUZAAD doi: 10.15829/1560-4071-2021-4594

[3] Sychev DA, Tkacheva ON, Kotovskaya Yu.V., Malaya I.P. Pharmacotherapy in elderly and senile persons. Moscow: LLC Congresschem, 2024. 124 с. [cited: 2024 Jul 2]. Available from: https://rgnkc.ru/images/metod_materials/Farmakoterapiya_2018.pdf (In Russ.)

[4] Сычев Д.А., Ткачева О.Н., Котовская Ю.В., Малая И.П. Фармакотерапия у лиц пожилого и старческого возраста / под ред. Москва: ООО «КОНГРЕССХИМ», 2024. 124 с. Режим доступа: https://rgnkc.ru/images/metod_materials/Farmakoterapiya_2018.pdf Дата обращения: 02.07.2024

[5] Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014;53(1):1–16. doi: 10.1007/s40262-013-0100-7

[6] Mueck W., Stampfuss J., Kubitza D., Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban // Clin Pharmacokinet. 2014. Vol. 53, N 1. P. 1–16. doi: 10.1007/s40262-013-0100-7

[7] Bayer Pharma AG. Xarelto (rivaroxaban) summary of product characteristics. cited 2024 Jul 2]. Available at: Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf.

[8] Bayer Pharma AG. Xarelto (rivaroxaban) summary of product characteristics. Режим доступа: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf. Дата обращения: 20.07.2024

[9] Zhao T, Chen Y, Wang D, et al. Identifying the dominant contribution of human cytochrome P450 2J2 to the metabolism of rivaroxaban, an oral anticoagulant. Cardiovasc Drugs Ther. 2022;36(1) 121–129. doi: 10.1007/s10557-020-07129-z

[10] Zhao T., Chen Y., Wang D., et al. Identifying the dominant contribution of human cytochrome P450 2J2 to the metabolism of rivaroxaban, an oral anticoagulant // Cardiovasc Drugs Ther. 2022. Vol. 36, N 1. P. 121–129. doi: 10.1007/s10557-020-07129-z

[11] Gouin-Thibault I, Delavenne X, Blanchard A, et al. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. J Thromb Haemost. 2017;15(2):273–283. doi: 10.1111/jth.13577

[12] Gouin-Thibault I., Delavenne X., Blanchard A., et al. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin // J Thromb Haemost. 2017. Vol. 15, N 2. P. 273–283. doi: 10.1111/jth.13577

[13] Campos-Staffico AM, Dorsch MP, Barnes GD, et al. Eight pharmacokinetic genetic variants are not associated with the risk of bleeding from direct oral anticoagulants in non-valvular atrial fibrillation patients. Front Pharmacol. 2022;13:1007113. doi: 10.3389/fphar.2022.1007113

[14] Campos-Staffico A.M., Dorsch M.P., Barnes G.D., et al. Eight pharmacokinetic genetic variants are not associated with the risk of bleeding from direct oral anticoagulants in non-valvular atrial fibrillation patients // Front Pharmacol. 2022. Vol. 13. P. 1007113. doi: 10.3389/fphar.2022.1007113

[15] Sychev D, Minnigulov R, Bochkov P, et al. Effect of CYP3A4, CYP3A5, ABCB1 gene polymorphisms on rivaroxaban pharmacokinetics in patients undergoing total hip and knee replacement surgery. High Blood Press Cardiovasc Prev. 2019;26(5):413–420. doi: 10.1007/s40292-019-00342-4

[16] Sychev D., Minnigulov R., Bochkov P., et al. Effect of CYP3A4, CYP3A5, ABCB1 gene polymorphisms on rivaroxaban pharmacokinetics in patients undergoing total hip and knee replacement surgery // High Blood Press Cardiovasc Prev. 2019. Vol. 26, N 5. P. 413–420. doi: 10.1007/s40292-019-00342-4

[17] Sychev DA, Sokolov AV, Reshetko OV, et al. Influence of ABCB1, CYP3A5 and CYP3A4 gene polymorphisms on prothrombin time and the residual equilibrium concentration of rivaroxaban in patients with non-valvular atrial fibrillation in real clinical practice. Pharmacogenet Genomics. 2022;32(9):301–307. doi: 10.1097/FPC.0000000000000483

[18] Sychev D.A., Sokolov A.V., Reshetko O.V., et al. Influence of ABCB1, CYP3A5 and CYP3A4 gene polymorphisms on prothrombin time and the residual equilibrium concentration of rivaroxaban in patients with non-valvular atrial fibrillation in real clinical practice // Pharmacogenet Genomics. 2022. Vol. 32, N 9. P. 301–307. doi: 10.1097/FPC.0000000000000483

[19] Shatalova NA, Mirzaev KB, Abdullaev ShP, et al. On the possible relationship between the presence of polymorphic variants of cyp3a4/5 cytochrome genes, their metabolic activity with rivaroxaban pharmacokinetics and the development of bleeding in patients with non-valvular atrial fibrillation and chronic kidney disease. Pharmateca. 2024;31(1):41–51. EDN: DBBBGF doi: 10.18565/pharmateca.2024.1.41-50

[20] Шаталова Н.А., Мирзаев К.Б., Абдуллаев Ш.П., и др. К вопросу о возможной взаимосвязи между наличием полиморфных вариантов генов цитохромов CYP3A4/5, их метаболической активностью с фармакокинетикой ривароксабана и развитием кровотечений у пациентов с неклапанной фибрилляцией предсердий и хронической болезнью почек // Фарматека. 2024. Т. 31. № 1. С. 41–51. EDN: DBBBGF doi: 10.18565/pharmateca.2024.1.41-50

[21] Nakagawa J, Kinjo T, Iizuka M, et al. Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation. Basic Clin Pharmacol Toxicol. 2021;128(2):297–304. doi: 10.1111/bcpt.1348

[22] Nakagawa J., Kinjo T., Iizuka M., et al. Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation // Basic Clin Pharmacol Toxicol. 2021. Vol. 128, N 2. P. 297–304. doi: 10.1111/bcpt.13488

[23] Wu T, Wu S, Li L, et al. The impact of ABCB1, CYP3A4/5 and ABCG2 gene polymorphisms on rivaroxaban trough concentrations and bleeding events in patients with non-valvular atrial fibrillation. Hum Genomics. 2023;17(1):59. doi: 10.1186/s40246-023-00506-3

[24] Wu T., Wu S., Li L., et al. The impact of ABCB1, CYP3A4/5 and ABCG2 gene polymorphisms on rivaroxaban trough concentrations and bleeding events in patients with non-valvular atrial fibrillation // Hum Genomics. 2023. Vol. 17, N 1. P. 59. doi: 10.1186/s40246-023-00506-3

[25] Mardi P, Abbasi B, Shafiee A, Afsharmoghaddam T. Pharmacogenetic approach for the prevention of rivaroxaban’s ADRs: A systematic review and meta-analysis. Genet Res (Camb). 2023;2023:6105320. doi: 10.1155/2023/6105320

[26] Mardi P., Abbasi B., Shafiee A., Afsharmoghaddam T. Pharmacogenetic approach for the prevention of rivaroxaban’s ADRs: A systematic review and meta-analysis // Genet Res (Camb). 2023. Vol. 2023. P. 6105320. doi: 10.1155/2023/6105320

[27] Li M, Xiao J, Yu T, et al. Analysis of hemorrhagic drug-drug interactions between P-gp inhibitors and direct oral anticoagulants from the FDA Adverse Event Reporting System. Expert Opin Drug Saf. 2024. P. 1–9. doi: 10.1080/14740338.2024.2376693

[28] Li M., Xiao J., Yu T., et al. Analysis of hemorrhagic drug-drug interactions between P-gp inhibitors and direct oral anticoagulants from the FDA Adverse Event Reporting System // Expert Opin Drug Saf. 2024. P. 1–9. doi: 10.1080/14740338.2024.2376693

[29] Grymonprez M, Carnoy L, Capiau A, et al. Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother. 2023;9(8):722–730. doi: 10.1093/ehjcvp/pvad070

[30] Grymonprez M., Carnoy L., Capiau A., et al. Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study // Eur Heart J Cardiovasc Pharmacother. 2023. Vol. 9, N 8. P. 722–730. doi: 10.1093/ehjcvp/pvad070

[31] Yang S, Xu Y, Zhang Y, et al. Effectiveness and safety of different oral anticoagulants with P-glycoprotein/CYP3A4 Inhibitors: A network meta-analysis. Curr Pharm Des. 2024;30(15):1167–1177. doi: 10.2174/0113816128293940240315073345

[32] Yang S., Xu Y., Zhang Y., et al. Effectiveness and safety of different oral anticoagulants with P-glycoprotein/CYP3A4 Inhibitors: A network meta-analysis // Curr Pharm Des. 2024. Vol. 30, N 15. P. 1167–1177. doi: 10.2174/0113816128293940240315073345

[33] Sychev DA, Chernyaeva MS, Rozhkova MA, et al, Safety of direct oral anticoagulants in the treatment of atrial fibrillation in geriatric patients: focus on clinically significant minor bleeding. Pharmateca. 2024;31(4):8–23. EDN: VWVGBF doi: 10.18565/pharmateca.2024.4.8-23

[34] Сычев Д.А., Черняева М.С., Рожкова М.А., и др. Безопасность прямых оральных антикоагулянтов в лечении фибрилляции предсердий у гериатрических пациентов: фокус на клинически значимые небольшие кровотечения // Фарматека. 2024. Т. 31. № 4. С. 8–23. EDN: VWVGBF doi: 10.18565/pharmateca.2024.4.8-23

[35] Sychev D, Mirzaev K, Cherniaeva M, et al. Drug-drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation. Drug Metab Pers Ther. 2020;35(3). doi: 10.1515/dmpt-2020-0127

[36] Sychev D., Mirzaev K., Cherniaeva M., et al. Drug-drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation // Drug Metab Pers Ther. 2020. Vol. 35, N3. doi: 10.1515/dmpt-2020-0127

[37] Online Encyclopedia for Genetic Epidemiology studies [Internet]. Hardy-Weinberg equilibrium calculator 2008 [cited 2021 Jun 14]. Available from: http://www.oege.org/software/hwe-mr-calc.shtml

[38] Online Encyclopedia for Genetic Epidemiology studies [электронный ресурс]. Hardy-Weinberg equilibrium calculator. 2008. Дата обращения 14.06.2021. Режим доступа: http://www.oege.org/software/hwe-mr-calc.shtml

RIGHTS & PERMISSIONS

Eco-Vector